Astrazeneca Pharma India Share Price
Sector: Major Drugs
You have to be logged in to add this to Watchlist.
Login or Register
6304.95 -192.55 (-2.96%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
6222.35
Today’s High
6588.95
52 Week Low
4050.15
52 Week High
8139.85
6305.45 -191.20 (-2.94%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
6220
Today’s High
6549.8
52 Week Low
4600.7
52 Week High
8139
Key Metrics
- Market Cap (In Cr) 16241.63
- Beta 0.49
- Div. Yield (%) 0.37
- P/B 22.81
- TTM P/E 243.26
- Peg Ratio 9.88
- Sector P/E 31.15
- D/E 0.03
- Open Price 6588.95
- Prev Close 6497.5
Astrazeneca Pharma India Analysis
Price Analysis
-
1 Week-10.47%
-
3 Months-0.9%
-
6 Month12.35%
-
YTD17.55%
-
1 Year39.61%
Risk Meter
- 50% Low risk
- 50% Moderate risk
- 50% Balanced Risk
- 50% High risk
- 50% Extreme risk
Astrazeneca Pharma India News
Stocks to Watch: Reliance Power, SpiceJet, Vodafone Idea, NHPC, PNB, and more
2 min read . 24 Sep 2024Stocks to buy or sell: Sumeet Bagadia recommends 5 breakout stocks today
2 min read . 24 Jul 2024Astrazeneca Pharma India Q4 Results Live : profit rise by 128.61% YOY
1 min read . 30 May 2024Astrazeneca Pharma India Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 1295.53
- Selling/ General/ Admin Expenses Total
- 332.9
- Depreciation/ Amortization
- 14.94
- Other Operating Expenses Total
- 183.62
- Total Operating Expense
- 1109.59
- Operating Income
- 185.94
- Net Income Before Taxes
- 219.54
- Net Income
- 161.51
- Diluted Normalized EPS
- 59.77
- Period
- 2024
- Total Assets
- 1078.03
- Total Liabilities
- 366.11
- Total Equity
- 711.92
- Tangible Book Valueper Share Common Eq
- 283.92
- Period
- 2024
- Cashfrom Operating Activities
- 27.86
- Cashfrom Investing Activities
- 21.74
- Cashfrom Financing Activities
- -44.37
- Net Changein Cash
- 5.23
- Period
- 2023
- Total Revenue
- 1002.97
- Selling/ General/ Admin Expenses Total
- 397.16
- Depreciation/ Amortization
- 16.26
- Other Operating Expenses Total
- 9.89
- Total Operating Expense
- 894.34
- Operating Income
- 108.63
- Net Income Before Taxes
- 134.1
- Net Income
- 99.29
- Diluted Normalized EPS
- 50.89
- Period
- 2023
- Total Assets
- 984.87
- Total Liabilities
- 396.18
- Total Equity
- 588.69
- Tangible Book Valueper Share Common Eq
- 235.48
- Period
- 2023
- Cashfrom Operating Activities
- 58.29
- Cashfrom Investing Activities
- 18.11
- Cashfrom Financing Activities
- -24.48
- Net Changein Cash
- 51.92
- Period
- 2022
- Total Revenue
- 805.6
- Selling/ General/ Admin Expenses Total
- 343.64
- Depreciation/ Amortization
- 16.95
- Other Operating Expenses Total
- 10.09
- Total Operating Expense
- 736.24
- Operating Income
- 69.36
- Net Income Before Taxes
- 83.04
- Net Income
- 61.6
- Diluted Normalized EPS
- 23.8
- Period
- 2022
- Total Assets
- 856.56
- Total Liabilities
- 345.17
- Total Equity
- 511.39
- Tangible Book Valueper Share Common Eq
- 204.56
- Period
- 2022
- Cashfrom Operating Activities
- 100.8
- Cashfrom Investing Activities
- 4.74
- Cashfrom Financing Activities
- -9.46
- Net Changein Cash
- 96.08
- Period
- 2021
- Total Revenue
- 813.56
- Selling/ General/ Admin Expenses Total
- 326.58
- Depreciation/ Amortization
- 20.13
- Other Operating Expenses Total
- 13.06
- Total Operating Expense
- 697.68
- Operating Income
- 115.88
- Net Income Before Taxes
- 127.09
- Net Income
- 93.3
- Diluted Normalized EPS
- 36.68
- Period
- 2021
- Total Assets
- 774.71
- Total Liabilities
- 318.54
- Total Equity
- 456.17
- Tangible Book Valueper Share Common Eq
- 182.47
- Period
- 2021
- Cashfrom Operating Activities
- 104.78
- Cashfrom Investing Activities
- 173.03
- Cashfrom Financing Activities
- -8.97
- Net Changein Cash
- 268.84
- Period
- 2020
- Total Revenue
- 831.81
- Selling/ General/ Admin Expenses Total
- 356.29
- Depreciation/ Amortization
- 18.58
- Other Operating Expenses Total
- 12.29
- Total Operating Expense
- 729.25
- Operating Income
- 102.56
- Net Income Before Taxes
- 113.97
- Net Income
- 72.21
- Diluted Normalized EPS
- 28.81
- Period
- 2020
- Total Assets
- 706.36
- Total Liabilities
- 341.92
- Total Equity
- 364.44
- Tangible Book Valueper Share Common Eq
- 145.78
- Period
- 2020
- Cashfrom Operating Activities
- 87.42
- Cashfrom Investing Activities
- -170.8
- Cashfrom Financing Activities
- -6.36
- Net Changein Cash
- -89.74
- Period
- 2019
- Total Revenue
- 728.29
- Selling/ General/ Admin Expenses Total
- 370.35
- Depreciation/ Amortization
- 14.92
- Other Operating Expenses Total
- 8.55
- Total Operating Expense
- 671.72
- Operating Income
- 56.57
- Net Income Before Taxes
- 72.67
- Net Income
- 54.45
- Diluted Normalized EPS
- 21.76
- Period
- 2019
- Total Assets
- 561.8
- Total Liabilities
- 261
- Total Equity
- 300.8
- Tangible Book Valueper Share Common Eq
- 120.32
- Period
- 2019
- Cashfrom Operating Activities
- 54.98
- Cashfrom Investing Activities
- 4.28
- Net Changein Cash
- 59.26
- Period
- 2018
- Total Revenue
- 571.99
- Selling/ General/ Admin Expenses Total
- 283.94
- Depreciation/ Amortization
- 14.74
- Other Operating Expenses Total
- 5.93
- Total Operating Expense
- 539.69
- Operating Income
- 32.3
- Net Income Before Taxes
- 43.8
- Net Income
- 25.91
- Diluted Normalized EPS
- 10.89
- Period
- 2018
- Total Assets
- 460.54
- Total Liabilities
- 213.61
- Total Equity
- 246.93
- Tangible Book Valueper Share Common Eq
- 98.77
- Period
- 2018
- Cashfrom Operating Activities
- 8.79
- Cashfrom Investing Activities
- -9.36
- Net Changein Cash
- -0.57
- Period
- 2024-09-30
- Total Revenue
- 408
- Selling/ General/ Admin Expenses Total
- 92.57
- Depreciation/ Amortization
- 9.32
- Other Operating Expenses Total
- 36.98
- Total Operating Expense
- 364.8
- Operating Income
- 43.2
- Net Income Before Taxes
- 51.03
- Net Income
- 38.43
- Diluted Normalized EPS
- 15.37
- Period
- 2024-09-30
- Total Assets
- 1241.3
- Total Liabilities
- 561.95
- Total Equity
- 679.35
- Tangible Book Valueper Share Common Eq
- 270.98
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 38.45
- Cashfrom Investing Activities
- 15.7
- Cashfrom Financing Activities
- -63.2
- Net Changein Cash
- -9.05
- Period
- 2024-06-30
- Total Revenue
- 387.52
- Selling/ General/ Admin Expenses Total
- 78.31
- Depreciation/ Amortization
- 3.91
- Other Operating Expenses Total
- 40.7
- Total Operating Expense
- 410.92
- Operating Income
- -23.4
- Net Income Before Taxes
- -15.16
- Net Income
- -11.79
- Diluted Normalized EPS
- 10.26
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 383.2
- Selling/ General/ Admin Expenses Total
- 83.3
- Depreciation/ Amortization
- 3.76
- Other Operating Expenses Total
- 36.96
- Total Operating Expense
- 337.57
- Operating Income
- 45.63
- Net Income Before Taxes
- 54.35
- Net Income
- 39.48
- Diluted Normalized EPS
- 15.79
- Period
- 2024-03-31
- Total Assets
- 1078.03
- Total Liabilities
- 366.11
- Total Equity
- 711.92
- Tangible Book Valueper Share Common Eq
- 283.92
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 27.86
- Cashfrom Investing Activities
- 21.74
- Cashfrom Financing Activities
- -44.37
- Net Changein Cash
- 5.23
- Period
- 2023-12-31
- Total Revenue
- 305.79
- Selling/ General/ Admin Expenses Total
- 91.56
- Depreciation/ Amortization
- 3.7
- Other Operating Expenses Total
- 50.89
- Total Operating Expense
- 294.44
- Operating Income
- 11.35
- Net Income Before Taxes
- 20.4
- Net Income
- 15.8
- Diluted Normalized EPS
- 6.32
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 311.07
- Selling/ General/ Admin Expenses Total
- 82.02
- Depreciation/ Amortization
- 3.67
- Other Operating Expenses Total
- 54.16
- Total Operating Expense
- 245.56
- Operating Income
- 65.51
- Net Income Before Taxes
- 73.38
- Net Income
- 52.37
- Diluted Normalized EPS
- 16.26
- Period
- 2023-09-30
- Total Assets
- 1101.55
- Total Liabilities
- 446.59
- Total Equity
- 654.97
- Tangible Book Valueper Share Common Eq
- 261.99
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 49.45
- Cashfrom Investing Activities
- 12.51
- Cashfrom Financing Activities
- -42.18
- Net Changein Cash
- 19.78
- Period
- 2023-06-30
- Total Revenue
- 295.47
- Selling/ General/ Admin Expenses Total
- 76.02
- Depreciation/ Amortization
- 3.8
- Other Operating Expenses Total
- 41.62
- Total Operating Expense
- 232.02
- Operating Income
- 63.45
- Net Income Before Taxes
- 71.4
- Net Income
- 53.86
- Diluted Normalized EPS
- 21.54
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 284.7
- Selling/ General/ Admin Expenses Total
- 81.06
- Depreciation/ Amortization
- 4.25
- Other Operating Expenses Total
- 45.17
- Total Operating Expense
- 269.34
- Operating Income
- 15.36
- Net Income Before Taxes
- 23.28
- Net Income
- 17.27
- Diluted Normalized EPS
- 18.84
- Period
- 2023-03-31
- Total Assets
- 984.87
- Total Liabilities
- 396.18
- Total Equity
- 588.69
- Tangible Book Valueper Share Common Eq
- 235.48
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 58.29
- Cashfrom Investing Activities
- 18.11
- Cashfrom Financing Activities
- -24.48
- Net Changein Cash
- 51.92
- Period
- 2022-12-31
- Total Revenue
- 249.81
- Selling/ General/ Admin Expenses Total
- 83.93
- Depreciation/ Amortization
- 4.13
- Other Operating Expenses Total
- 37.82
- Total Operating Expense
- 217.35
- Operating Income
- 32.46
- Net Income Before Taxes
- 39.46
- Net Income
- 29.3
- Diluted Normalized EPS
- 11.72
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Astrazeneca Pharma India Technical
Moving Average
SMA
- 5 Day6992.91
- 10 Day7226.53
- 20 Day7265.06
- 50 Day7295.71
- 100 Day7005.33
- 300 Day6329.9
Astrazeneca Pharma India Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Pfizer
- 5122.75
- -61.8
- -1.19
- 6452.85
- 3977
- 23435.42
- Neuland Laboratories
- 14902
- 37.7
- 0.25
- 16544.75
- 4928
- 19119.1
- Astrazeneca Pharma India
- 6304.95
- -192.55
- -2.96
- 8139.85
- 4050.15
- 15762.38
- Unichem Laboratories
- 860.7
- -20.9
- -2.37
- 949.85
- 401.1
- 6059.82
- Themis Medicare
- 287.6
- 1.2
- 0.42
- 313.65
- 152.65
- 2647.07
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Pfizer
- 43.26
- 6.59
- 18.43
- 24.05
- Neuland Laboratories
- 60.01
- 14.89
- 14.98
- 11.99
- Astrazeneca Pharma India
- 108.05
- 22.81
- 20.1
- 10.27
- Unichem Laboratories
- -
- 2.63
- -2.1
- -3.99
- Themis Medicare
- 60.63
- 6.97
- 18.03
- 14.96
Astrazeneca Pharma India Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 13-Nov-24
- Quarterly Results
- 08-Aug-24
- Quarterly Results
- 27-May-24
- Audited Results & Dividend
- 08-Feb-24
- Quarterly Results
- 09-Nov-23
- Quarterly Results
- 14-Aug-23
- Quarterly Results
- 30-May-23
- Audited Results & Dividend
- 10-Feb-23
- Quarterly Results
- 11-Nov-22
- Quarterly Results
- 08-Aug-22
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 08-Aug-24
- 16-Jul-24
- AGM
- 07-Apr-24
- 06-Mar-24
- POM
- 08-Feb-24
- 05-Jan-24
- POM
- 14-Aug-23
- 30-May-23
- AGM
- 27-Feb-23
- 25-Jan-23
- POM
- 08-Aug-22
- 26-May-22
- AGM
- 31-Mar-22
- 23-Feb-22
- POM
- 09-Aug-21
- 26-May-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 27-May-24
- 05-Jul-24
- 05-Jul-24
- 24
- 30-May-23
- 14-Jul-23
- 14-Jul-23
- 16
- 26-May-22
- 08-Jul-22
- 07-Jul-22
- 8
- 09-Aug-21
- 20-Aug-21
- 18-Aug-21
- 2